A pharmacy-based intervention may help increase SGLT2 inhibitor use for patients with type 2 diabetes and chronic kidney ...

Patients with systemic lupus erythematosus and diabetes who received sodium-glucose cotransporter 2 inhibitors exhibited ...

At present, around 59 million adults worldwide have diabetes, about 64 million are diagnosed with heart failure, and ...

While type 1 and type 2 diabetes typically occupy distinct places in healthcare, research is showing an increase of patients ...

A new study has shown that a group of diabetes drugs called SGLT2 inhibitors may increase the risk of a rare but dangerous ...

Scott-Moncrieff: The most important first step is deciding which treatment is right for that individual cat, because monitoring differs depending on whether you choose insulin or an SGLT2 ...

A new study shows that older adults with type 2 diabetes who start treatment with sodium–glucose cotransporter-2 (SGLT-2) inhibitors—such as empagliflozin (Jardiance) and dapagliflozin (Farxiga)—or ...

Launch targets $16 billion SGLT-2 inhibitor market that serves 33 million type II diabetics in the US, many of whom are ...

For patients with type 2 diabetes, there is an association between glucagon-like peptide-1 receptor agonist (GLP-1 RA) use ...

People with either type 1 or type 2 diabetes have a dramatically higher risk of sudden cardiac death, which occurs when the ...

Semaglutide, a GLP-1 receptor agonist (RA), was associated with a significantly lower risk for adult-onset epilepsy in patients with diabetes than other glucose-lowering drugs (GLDs). Notably, this ...

For an average 30-year-old with type 1 or 2 diabetes, life expectancy was 14.2 and 7.9 years shorter, respectively, compared ...